Federal health regulators issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, after months of lobbying by patient advocates urging approval.
WASHINGTON — Federal health regulators issued a negative review Monday of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, after months of lobbying by patient advocates urging approval.
The meeting is being closely watched as an indicator of the FDA’s approach to experimental drugs with imperfect data and its ability to withstand outside pressure. Amylyx’s drug is a combination of two older drugs: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine. Amylyx has patented the combination in a powder and says the chemicals help protect cells from early death.
After further discussions with regulators last summer, Amylyx decided to submit its drug for approval based on the initial study plus survival data gathered afterwards. The company said that data showed patients who took the drug lived about six months longer than those taking a dummy drug. Currently, there are only two FDA-approved drugs for ALS, the more effective of which extends life by several months.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Read more »
FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease
Read more »
FDA Skeptical of Benefits From Experimental ALS DrugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease
Read more »
FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Read more »
The FDA is expected to authorize 2nd boosters for people 50 and up - Alaska Public MediaAnyone 50 and older could soon be eligible for a second booster dose of the Moderna or Pfizer-BioNtech COVID-19 vaccine. The plan comes as evidence increases that protection from three shots is fading and a fourth shot would help boost immunity back up.
Read more »